Want to see AU:CMB full AI Analyst Report?
Top Page
Regeneus Ltd.
(Sydney:CMB)
Select Model
Select Model
Rating:52Neutral
Price Target:
AU$0.46
â–¼(-3.19% Downside)
Action:Reiterated
Date:09/24/26
The score is held back primarily by weak financial performance—persistent losses and ongoing cash burn that elevate funding/dilution risk—despite balance sheet stabilization. Technical momentum is a notable positive and lifts the score, while valuation remains unattractive/unclear due to negative earnings and no dividend support.
Positive Factors
Integrated operating model
Regeneus operates across several stages of the regenerative-medicine value chain rather than focusing only on early research. This integrated model can support continuity from therapy development through clinical use and commercialization, providing a durable platform for future product advancement.
Negative Factors
Persistent unprofitability
Regeneus remains in a prolonged loss-making phase, with operating and net losses continuing across five consecutive years. Persistent unprofitability reduces internally generated funding capacity and makes the business more dependent on successful commercialization or external capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Integrated operating model
Regeneus operates across several stages of the regenerative-medicine value chain rather than focusing only on early research. This integrated model can support continuity from therapy development through clinical use and commercialization, providing a durable platform for future product advancement.
Read all positive factors
Regeneus Ltd. (CMB) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$13.24M
Dividend YieldN/A
Average Volume (3M)2.88K
Price to Earnings (P/E)―
Beta (1Y)0.04
Revenue Growth-4.24%
EPS Growth33.39%
CountryAU
Employees2
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.25
Shares Outstanding29,431,917
10 Day Avg. Volume11
30 Day Avg. Volume2,880
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)4.31
Price to Sales (P/S)15.99
P/FCF Ratio-3.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)N/A
Regeneus Ltd. Business Overview & Revenue Model
Company Description
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease...
Regeneus Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
52
Neutral
Cash Flow
24
Negative
| Breakdown | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2023 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 641.64K | 670.06K | 719.00 | 0.00 | 0.00 |
| Gross Profit | 578.70K | 464.32K | 79.78K | -6.42K | -24.96K |
| EBITDA | -4.36M | -3.80M | -1.98M | -3.08M | -4.74M |
| Net Income | -4.10M | -3.84M | -2.26M | -3.38M | -4.31M |
Balance Sheet | |||||
| Total Assets | 3.76M | 3.30M | 5.65M | 2.46M | 2.55M |
| Cash, Cash Equivalents and Short-Term Investments | 1.12M | 166.41K | 2.86M | 302.79K | 164.40K |
| Total Debt | 164.89K | 482.71K | 468.32K | 1.95M | 1.01M |
| Total Liabilities | 1.38M | 1.46M | 2.87M | 2.59M | 1.48M |
| Stockholders Equity | 2.38M | 1.84M | 2.78M | -1.81M | 1.07M |
Cash Flow | |||||
| Free Cash Flow | -2.81M | -5.25M | -155.86K | -660.46K | -3.60M |
| Operating Cash Flow | -2.81M | -5.24M | -155.86K | -660.46K | -3.59M |
| Investing Cash Flow | -322.64K | -333.48K | -416.13K | -48.13K | -8.47K |
| Financing Cash Flow | 4.24M | 2.88M | 3.13M | 916.27K | -97.83K |
Regeneus Ltd. Technical Analysis
Negative
0.47
Price Trends
0.47
Negative
0.45
Positive
0.46
Negative
Market Momentum
>-0.01
Positive
34.86
Neutral
6.06
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CMB, the sentiment is Negative. The current price of 0.47 is below the 20-day moving average (MA) of 0.50, above the 50-day MA of 0.47, and above the 200-day MA of 0.46, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 34.86 is Neutral, neither overbought nor oversold. The STOCH value of 6.06 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:CMB.
Regeneus Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | AU$13.24M | -1.79 | -247.44% | ― | -4.24% | 33.39% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$2.29B | -28.67 | -10.06% | ― | 555.67% | 49.08% | |
43 Neutral | AU$177.06M | -10.19 | -36.83% | ― | 51.07% | -47.63% | |
43 Neutral | AU$5.14M | -0.94 | -52.04% | ― | 32.22% | -26.53% | |
42 Neutral | AU$3.35M | -0.28 | -617.89% | ― | ― | 13.67% | |
40 Underperform | AU$20.28M | -5.71 | -132.20% | ― | ― | -200.00% |
* Healthcare Sector Average
AU:CMB
Regeneus Ltd.
0.45
-0.03
-6.25%
AU:CYP
Cynata Therapeutics Limited
0.01
-0.24
-95.65%
AU:1AI
Living Cell Technologies
0.01
0.00
0.00%
AU:MSB
Mesoblast Limited
1.83
-0.77
-29.62%
AU:OCC
Orthocell Ltd
0.53
-0.74
-58.33%
AU:TRP
Tissue Repair Ltd
0.08
-0.22
-72.33%
Regeneus Ltd. Corporate Events
Cambium Bio Sets Virtual 2026 AGM With Expert Report for Shareholders
Oct 7, 2026
Cambium Bio Limited has called shareholders to its 2026 Annual General Meeting, which will be held virtually on 9 November 2026 at 11:00am Sydney time via an online webcast platform. The company has released its Notice of Meeting on the ASX and it...
Cambium Bio Calls Online AGM as Expert Backs Share Placement Plan
Oct 7, 2026
Cambium Bio Limited has convened its 2026 Annual General Meeting for 9 November, to be held entirely online via a dedicated meeting platform. Shareholders are invited to participate remotely or submit proxy forms, with the 2026 Annual Report avail...
Cambium Bio Plans Major ASX Share Placement to Bolster Capital Base
Oct 7, 2026
Cambium Bio Limited has announced a proposed placement of ordinary fully paid shares on the ASX, reflecting its use of equity issuance as a key funding mechanism. The company is leveraging its listed status and disclosure framework to structure th...
Cambium Bio sets online AGM date and director nomination deadline
Sep 28, 2026
Cambium Bio Limited has scheduled its 2026 Annual General Meeting to be held online on 9 November at 11:00 a.m. Sydney time, providing shareholders with digital access to attend, ask questions and vote. The company has set 2 October at 5:00 p.m. a...
Cambium Bio Options Lapse, Trimming Potential Share Dilution
Sep 24, 2026
Cambium Bio Limited has notified the market of changes to its issued capital following the expiry of a tranche of options. The company remains listed on the ASX under the ticker CMB, with this announcement reflecting the routine management of its ...
Cambium Bio Issues 160,000 Unquoted Options to Support Future Growth
Sep 23, 2026
Cambium Bio Limited has notified the market of the issuance of 160,000 unquoted options under the security code CMBAQ, with various exercise prices and expiry dates and an issue date of May 20, 2025. The additional unquoted options expand the comp...
Cambium Bio locks in A$10.85m to fund Phase 3 dry eye trial
Sep 16, 2026
Cambium Bio has secured a total funding package of A$10.85 million to support its pivotal Phase 3 programme for Elate Ocular®, combining a A$7.1 million equity placement with a previously arranged A$3.75 million research and development tax i...
Cambium Bio Plans New Share Placement to Bolster Capital Base
Sep 16, 2026
Cambium Bio Limited, trading on the ASX under the ticker CMB, is a biotechnology company developing biological products and leveraging public equity markets to support its growth. Its focus on securing capital underscores its status as an emerging...
Cambium Holdings Rectifies Late ASX Filings on Substantial Shareholder Changes
Sep 16, 2026
Cambium Holdings Limited has disclosed that notices of changes in interests for two substantial shareholders, Zheng Yang Biomedical Technology Co. Ltd. and Cyntec Co. Ltd., were lodged late with the ASX. The company attributes the delay, covering ...
Cambium Bio Corrects Option Expiry Date in ASX Securities Issue Filing
Sep 2, 2026
Cambium Bio Limited has updated its disclosure to the ASX regarding a proposed issue of securities, correcting the stated expiry date of certain options to 28 August 2031. The amendment, which relates to a prior announcement lodged on 1 September ...
Cambium Bio Issues 2 Million Unquoted Options
Sep 2, 2026
Cambium Bio Limited has notified the market of the issue of 2,000,000 unquoted options under the ASX Appendix 3G framework. The options, carrying various exercise prices and expiry dates, were issued on 31 August 2026 and are not intended to be qu...
Cambium Bio Plans Issue of 2 Million Options in ASX Placement
Sep 1, 2026
Cambium Bio Limited has notified the ASX of a proposed issue of options as part of a placement or similar capital initiative. The company plans to issue up to 2,000,000 options with various expiry dates and exercise prices, with a proposed issue d...
Cambium Bio Files Updated Corporate Governance Statement and Appendix 4G
Aug 28, 2026
Cambium Bio Limited has lodged its updated corporate governance statement for the year ended 30 June 2026, confirming it is available on the company’s website and has been approved by the board as of 28 August 2026. The accompanying Appendix...
Cambium Bio Narrows Annual Loss as Asset Backing Improves
Aug 28, 2026
Cambium Bio Limited reported revenue from ordinary activities of $642,000 for the year to 30 June 2026, down 4%, while other income jumped 334% to $596,000, narrowing its loss as net profit attributable to members came in at a $4.1 million loss, a...
Cambium Bio Tightens Securities Trading Rules to Bolster Governance
Aug 4, 2026
Cambium Bio Limited has released an updated Securities Trading Policy outlining stricter rules for how key management personnel and employees may buy or sell company securities. The policy defines closed trading periods around financial reporting ...
Cambium Bio issues 2.1 million new shares under disclosure relief
Jul 23, 2026
Cambium Bio Limited has issued 2.1 million new ordinary shares on 24 July 2026, under provisions allowing the company to do so without a full disclosure document to investors. The company has confirmed it remains compliant with its continuous disc...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.